Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - captopril -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - captopril -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - captopril -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; maize starch; stearic acid; sodium starch glycollate - hypertension. treatment of hypertension. in using zedace, consideration should be given to the risk of neutropenia/ agranulocytosis (see precautions). zedace is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the hypotensive effects of captopril and thiazides are approximately additive. myocardial infraction. zedace may be used to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to decrease the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for commencement of therapy beyond three days postinfarction. heart failure. treatment of heart failure. it is recommended that zedace be administered together with a diuretic in symptomatic patients. diabetic nephropathy. zedace is also indicated in the treatment of diabetic nephropathy in patients with type i insulin- dependent diabetes mellitus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - captopril, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; maize starch; stearic acid; sodium starch glycollate - hypertension. treatment of hypertension. in using zedace, consideration should be given to the risk of neutropenia/ agranulocytosis (see precautions). zedace is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the hypotensive effects of captopril and thiazides are approximately additive. myocardial infraction. zedace may be used to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to decrease the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for commencement of therapy beyond three days postinfarction. heart failure. treatment of heart failure. it is recommended that zedace be administered together with a diuretic in symptomatic patients. diabetic nephropathy. zedace is also indicated in the treatment of diabetic nephropathy in patients with type i insulin- dependent diabetes mellitus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - captopril -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: crospovidone; sodium stearylfumarate; lactose; povidone; microcrystalline cellulose - hypertension: monopril is indicated in the treatment of mild to moderate hypertension. monopril is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monopril in severe or renovascular hypertension. heart failure: monopril is indicated for the management of heart failure when added to conventional therapy, including diuretics.